Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana

被引:35
作者
Al-Mohammed, HI [1 ]
Chance, ML [1 ]
Bates, PA [1 ]
机构
[1] Univ Liverpool Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
关键词
D O I
10.1128/AAC.49.8.3274-3280.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学]; 100705 [微生物与生化药学];
摘要
The sensitivities of Leishmania mexicana amastigote and promastigote forms to amphotericin B were investigated in vitro and found to be strongly influenced by the culture media used. When differences in culture media were minimized, there was no significant difference in the 50% inhibitory concentration values between the two life cycle stages. Stable amphotericin B-resistant amastigote and promastigote lines were produced by the application of increasing drug pressure to long-term cultures. Lines capable of growth in concentrations of amphotericin B lethal to normal parasites were produced. Compared to normal parasites, these amphotericin-resistant lines showed marked differences in membrane sterol compositions, with very high levels of 4,14,dimethyl-cholesta-8,24-dienol and other methyl sterols. They also showed a consistent morphological feature, the presence of multilamellar membrane-like material in the flagellar pocket, revealed by transmission electron microscopy. Amphotericin-resistant parasites were capable of infecting BALB/c mice, but the resulting lesion growth was slower than that after infection with normal parasites. However, unlike normal parasites, the amphotericin-resistant parasites were unaffected by experimental chemotherapy with ampbotericin B. These results show that amphotericin B resistance could arise as a result of increased clinical use of amphotericin B therapy.
引用
收藏
页码:3274 / 3280
页数:7
相关论文
共 41 条
[1]
Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters [J].
Agrawal, AK ;
Agrawal, A ;
Pal, A ;
Guru, PY ;
Gupta, CM .
JOURNAL OF DRUG TARGETING, 2002, 10 (01) :41-45
[2]
Chemotherapy of canine leishmaniosis [J].
Baneth, G ;
Shaw, SE .
VETERINARY PARASITOLOGY, 2002, 106 (04) :315-324
[3]
AXENIC CULTIVATION AND CHARACTERIZATION OF LEISHMANIA-MEXICANA AMASTIGOTE-LIKE FORMS [J].
BATES, PA ;
ROBERTSON, CD ;
TETLEY, L ;
COOMBS, GH .
PARASITOLOGY, 1992, 105 :193-202
[4]
Heated amphotericin to treat leishmaniasis [J].
Bau, P ;
Bolard, J ;
Dupouy-Camet, J .
LANCET INFECTIOUS DISEASES, 2003, 3 (04) :188-188
[5]
Carrier effects on biological activity of amphotericin B [J].
Brajtburg, J ;
Bolard, J .
CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (04) :512-+
[6]
A policy for leishmaniasis with respect to the prevention and control of drug resistance [J].
Bryceson, A .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2001, 6 (11) :928-934
[7]
Chance Michael L., 1997, P163
[8]
Leishmaniasis: Recognition and management with a focus on the immunocompromised patient [J].
Choi C.M. ;
Lerner E.A. .
American Journal of Clinical Dermatology, 2002, 3 (2) :91-105
[9]
Chemotherapy of leishmaniasis [J].
Croft, SL ;
Yardley, V .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (04) :319-342
[10]
DAVIES CR, 2004, BRIT MED J, V326, P377